Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients

Hepatology International

Volumn 10, Issue 5, 2016, Pages 789-798

  Ji, Dong ^a   Chen, Guo Feng ^a   Wang, Cheng ^b,c   Wang, Yu Dong ^b   Shao, Qing ^a   Li, Bing ^a   Zhao, Jun ^a   You, Shao Li ^a   Hu, Jin Hua ^a   Liu, Jia Liang ^a   Niu, Xiao Xia ^a   Chen, Jing ^b   Lu, Lei ^b   Wu, Vanessa ^b   Lau, George ^a,b  

^a BEIJING 302 HOSPITAL   (China)

^b Humanity and Health Medical Centre   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis C; Direct acting antivirals; Genotype 1b; Ribavirin free

Indexed keywords

CEFACLOR; DACLATASVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; ASTHENIA; CHINESE; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; LEUKOPENIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTOPENIA; TREATMENT DURATION; ADOLESCENT; CHINA; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHINA; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84979204257     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-016-9755-0     Document Type: Article

References (46)

1. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61(1): 77–87
2. Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2014; 29(3): 545–553
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49(4): 1335–1374
4. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54(4): 1433–1444
5. Wei L, Hou JL. [The guideline of prevention and treatment for hepatitis C: a 2015 update]. Zhonghua Gan Zang Bing Za Zhi 2015; 23(12): 906–923
6. Kershenobich D, Munoz L, Male R, Gaytan J, Sanchez F. Proceed with caution: peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials. Hepatology 2010; 52(6): 2240–2241
7. (author reply 2241–2242)
8. Solbach P, Wedemeyer H. The new era of interferon-free treatment of chronic hepatitis C. Viszeralmedizin 2015; 31(4): 290–296
9. Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res 2015; 6(3): 301–310
10. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370(3): 211–221
11. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370(20): 1879–1888
12. Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62(3): 932–954
13. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Annals of internal medicine 2015; 162(6): 397–406
14. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55(3): 403–408
15. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53(6): 1013–1021
16. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41(1): 48–54
17. Bourliere M, Bronowicki JP, De Ledinghen V, Hezode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15(4): 397–404
18. Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. The American journal of gastroenterology 2005; 100(3): 643–651
19. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48(2): 418–431
20. Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014; 40(6): 657–675
21. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Annals of internal medicine 2015; 162(6): 407–419
22. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014; 60(1): 37–45
23. Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996
24. Who Commission on Macroeconomics and Health. Report of the WHO Commission on Macroeconomics and Health. Geneva: World Health Organization; 2002
25. Omata M, Kanda T, Yokosuka O, Crawford D, Al-Mahtab M, Wei L, et al. Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatol Int 2015; 9(4): 486–507
26. Singh T, Guirguis J, Anthony S, Rivas J, Hanouneh IA, Alkhouri N. Sofosbuvir based treatment is safe and effective in patients with chronic hepatitis C infection and end-stage renal disease: a case series. Liver Int 2016; 36(6):802–806
27. Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64(6):1224–1231
28. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015; 15(6):645–653
29. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368(20): 1878–1887
30. Kayali Z, Schmidt WN. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmgenomics Pers Med 2014; 7: 387–398
31. Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2015; 42(3): 258–272
32. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370(16): 1483–1493
33. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370(20): 1889–1898
34. Younossi ZM, Stepanova M, Zeuzem S, Dusheiko G, Esteban R, Hezode C, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 2014; 61(2): 228–234
35. Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015; 7: 51–70
36. Fazel Y, Lam B, Golabi P, Younossi Z. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert Opin Drug Saf 2015; 14(8): 1317–1326
37. Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology 2016; 63(4): 1112–1119
38. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut 2015; 64(11): 1824–1833
39. Dickson DJ, Pfeifer JD. Real-world data in the molecular era-finding the reality in the real world. Clin Pharmacol Ther 2016; 99(2): 186–197
40. Mahajan R. Real world data: Additional source for making clinical decisions. Int J Appl Basic Med Res 2015; 5(2): 82
41. Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. N Engl J Med 2014; 370(20): 1869–1871
42. Mccarthy M. Fake medicines are undermining global efforts to combat infectious disease, says US journal. BMJ 2015; 350: h2137
43. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 2016; pii: S0168–8278(16)30113–1. doi:10.1016/j.jhep.2016.04.008
44. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014; 124(8): 3352–3363
45. Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, Liang TJ, et al. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology 2015; 149(1): 190–200 e192
46. Mondelli MU. Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C. Gastroenterology 2015; 149(1): 25–28